Novo Nordisk stock rose after the Danish pharma giant posted better-than-expected quarterly earnings even as sales of its ...

While they share similarities, there are differences, particularly between the drugs semaglutide and tirzepatide.

Shares have slumped 60% since the Wall Street Journal reported in April that the company was preparing to file for bankruptcy ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Shares in Novo Nordisk were still up after Q1 2025 witnessed a total revenue jump by 18%, compared to Q1 2024.

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

U.S. drug distributor Cencora raised its annual profit forecast on Wednesday, driven by robust demand for costly specialty medicines and weight-loss drugs.

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, cut its ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Obesity drugmaker Novo Nordisk has today downgraded its 2025 sales forecast, ending a four-year stretch of steady guidance ...

With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention.

As weight-loss injectables like Ozempic skyrocket in popularity, a new offshoot trend is starting to take hold: microdosing. But experts have concerns.